Your time:
All times refer to CET. Event time:
Sunday, April 21, 2024
| Time | Program | |||||
| 17:30 - 21:00 | Welcome reception Markthalle Basel (Steinentorberg 20, CH-4051 Basel) Conference Badge pick-up possible. Please bring along your QR-code and ID-card for registration. The welcome reception is a networking opportunity. Small bites and drinks are provided on site for free. For later in the evening or the larger appetite, food is available in the adjacent charming international food-court at participant’s own expenses: altemarkthalle.ch Location 
sponsored by
|
|||||
Monday, April 22, 2024
| Time | Program | |||||
| 08:00 - 09:45 | Citeline pre event (by invitation only) Room Osaka/Samarkand ![](http://swissbiotechday.ch/wp-content/uploads/2022/02/sba-logo.png"){kind=logo} 
|
|||||
| 08:30 | Early bird badge pick up (advised) Entrance |
|||||
| 10:00 - 11:00 | Swiss Biotech Association General Assembly (by invitation only) Room Sydney |
|||||
| 11:00 | Registration opens Entrance |
|||||
| 11:00 - 11:45 | Press conference (media only) Room Rio |
|||||
| 11:00 - 18:45 | Exhibition Foyer 2nd floor and Hall 4.1 |
|||||
| Poster presentations Hall 4.1 |
||||||
| Global Village Room San Francisco |
||||||
| Partnering Room San Francisco and Hall 4.1 sponsored by  |
||||||
| 11:30 - 13:00 | Lunch grab & go Foyer 2nd floor and Hall 4.1 |
|||||
| 12:30 - 14:00 | Plenary session I Room Montreal Moderation Monika Jones Welcome local host Kaspar Sutter, Head of the Department of Economic, Social and Environmental Affairs, Canton of Basel-Stadt Welcome organizer Michael Altorfer, CEO, Swiss Biotech Association European Biosolutions Coalition Sofie Carsten Nielsen, Director, European Biosolutions Coalition Marit Hvithamar Rystrøm, Leading Senior Advisor, European Biosolutions Coalition Panel on Longevity Patrick Aebischer, President emeritus, EPFL Greg Behar, CEO, Recipharm Elisabeth Roider, Partner and Chief Scientific & Medical officer, Maximon AG Alejandro Ocampo, Assistant Professor, Université de Lausanne Amalio Telenti, Executive Vice President, Vir Biotechnology Life Science Cares Patrick Amstutz, President, Swiss Biotech Association Div Gupta, Partner, Cooley |
|||||
| 14:00 - 15:00 | Coffee break | |||||
| 14:30 - 18:30 | Parallel tracks | |||||
| Emerging biotech company presentations – presented by Pureos Bioventures Room Singapore |
Panel discussions Room Sydney |
Advanced biotech company presentations – presented by Lonza Room Osaka |
Clinical stage biotech company presentations – presented by Celonic Room Samarkand |
Panel discussions Room Rio |
Panel discussions Marriott Hotel |
|
| + Celonic | ||||||
| + Pureos Bioventures | 14:30 - 15:15 + Panel 1: Driving Clinical Development During Challenging Financial Times by Fortrea |
+ Lonza Group AG | + Vaccentis | 14:30 - 15:15 + Panel 5: ADCs & beyond by WuXi XDC |
14:30 - 15:15 + Panel 9: Incentives to promote drug innovation by Incyte Biosciences |
|
| + Engimmune Therapeutics | + Basilea | + Santhera | ||||
| + Antion Biosciences | + Hangzhou HealSun Biopharm | + Muvon Therapeutics | ||||
| + Ymmunobio | + Alphamol | + Endogena | ||||
| + Haya Therapeutics | 15:30 - 16:15 + Panel 2: How regulators can best support innovation by Swissmedic |
+ Labcorp | + Azafaros | 15:30 - 16:15 + Panel 6: Innovate & Educate by Virdis Group Sàrl |
15:30 - 16:15 + Panel 10: Maintaining Funding Flexibility by KPMG Switzerland |
|
| + Orio Therapeutics | + Cytiva | AB2 Bio | ||||
| + Seito | Break | Break | ||||
| + NewBiologix | + Qiagen | + Gnubiotics | ||||
| + Panel 13: More with less by Sartorius Room Montreal |
||||||
| 16:30 - 17:15 + Panel 3: Achieve initial market access in Switzerland by Innomedica |
+ Elsevier | + Canvirex | 16:30 - 17:15 + Panel 7: Legal Chapter |
16:30 - 17:15 + Panel 11: Life Science Cares |
||
| 16:45 - 17:30 + Start-up pitch Nucleate |
+ The Jackson Laboratory | + Stalicla | ||||
| + IPS | + FatiAbGen | |||||
| + Stämm Vegh | ||||||
| 17:30 - 18:15 + Panel 4: International Alliances |
+ Nerviano Medical Sciences srl | 17:30 - 18:15 + Panel 8: Drug Discovery for Rare Diseases: from Genes to Treatments by The Jackson Laboratory (JAX) |
17:30 - 18:15 + Panel 12: Focus the development effort to maximize commercial potential by Syneos Health Switzerland GmbH |
|||
| 17:45 - 18:30 + Venture Leader pitch |
+Inizio | |||||
| 18:00 - 18:45 | International reception of the Global Village Room San Francisco |
|||||
| 18:45 - 21:00 | Evening reception Foyer 2nd floor sponsored by  |
|||||
Tuesday, April 23, 2024
| Time | Program | |||||
| 07:15 | Registration opens Entrance |
|||||
| 07:30 - 17:00 | Partnering Room San Francisco and Hall 4.1 sponsored by |
|||||
| 09:00 - 18:30 | Exhibition Foyer 2nd floor and Hall 4.1 |
|||||
| Poster presentations Hall 4.1 |
||||||
| Global Village Room San Francisco |
||||||
| 09:00 - 09:45 | Pitching sessions | |||||
| + Next Generation Organ-on-chip & Organoids Room Singapore |
+ Recent Developments and Future Avenues in Cell & Gene Therapies Room Sydney |
+ Innovative Companies in Healthspan and Longevity Room Rio |
+ Investors pitch to the audience Marriott Hotel |
|||
| 10:00 - 12:00 | Plenary session II Room Montreal Moderation Monika Jones Decoding Swiss Biotech – the investors perspective Seth Lewis, Senior Vice President Investor Relations, Communications and Strategy, Molecular Partners Francesco De Rubertis, Co-Founder and Partner, Medicxi Dominik Escher, Managing Partner, Pureos Bioventures Matthias Fehr, Head Private Equity, HBM Partners Nicholas Riddle, Managing Director Healthcare Investment Banking, JP Morgan Pharma partnering panel Matthias Müllenbeck, SVP, Head of Global Business Development & Alliance Management, Merck KGaA Richard Girling, Partner, Centerview Partners Frances Stocks Allen, Partner, Cooley Brad Robling, Vice President, Eli Lilly and Company Site Selection Report André Güdel, Head International Business Development, KPMG Swiss Biotech Report Frederik Schmachtenberg, Partner, EY Swiss Biotech Success Stories Awards Luca Bolliger, Jury President |
|||||
| 12:00 - 13:30 | Lunch Foyer 2nd floor and Hall 4.1sponsored by  |
|||||
| 12:00 - 16:45 | Parallel tracks | |||||
| Emerging biotech company presentations – presented by Pureos Bioventures Room Singapore |
Clinical stage biotech company presentations – presented by Celonic Room Sydney |
Advanced biotech company presentations – presented by Lonza Room Osaka |
Panel discussions Room Samarkand |
Panel discussions Room Rio |
Panel discussions Marriott Hotel |
|
| 12:00 - 12:45 + Panel 14: Microbiome - Pharmabiome (R&D) |
||||||
| 12:15 - 13:00 + Pitch industrial biotech |
12:15 - 13:00 + Panel 19: Lab automation panel |
12:15 - 13:00 + Pitching health tech |
||||
| 12:40 – 13:00 + Celonic |
||||||
| + Pitching session: Innovate beyond Switzerland Room Montreal |
||||||
| + NovaGo Therapeutics | + Molecular Partners | + FoRx Therapeutics | 13:00 - 13:45 + Panel 15 for Pitch industrial biotech |
13:00 - 13:45 + Pitching Lab automation |
13:00 - 13:45 + Panel 23: Health-tech panel by Lenz & Staehelin |
|
| + AdRegeneer | + 4Teen4 Pharmaceuticals | + J&J Innovation | ||||
| + Osasuna Therapeutics | + ImmunOS | + Scandion Oncology | ||||
| + Amphilix | + Addex Therapeutics | + Selvita S.A. | ||||
| + Adoram Therapeutics | + Eli Lilly | + LS Instruments | 14:00 - 14:45 + Panel 16: Radioligand Therapy by Molecular Partners |
14:00 - 14:45 + Panel 20: Talent Trek: Biotech’s needs, challenges and opportunities by CTC Resourcing Solutions |
14:00 - 14:45 + Panel 24: Networking in biotech by the YVC Collective |
|
| + Tenpoint Tx | + GeNeuro | + Trialize | ||||
| Break | Break | + Lonza Group AG | ||||
| + Phialogics | + Topadur Pharma | + EspeRare Fondation | ||||
| 14:30 - 15:30 | Coffee break |
|||||
| + Mysthera Therapeutics | + Cutiss | + Maiwald | 15:00 - 15:45 + Panel 17: Pioneering Partnerships: Biotech alliances to patient impact by CSL Behring AG |
15:00 - 15:45 + Panel 21: AMR: From Awareness to Action. The time is now to invest. |
15:00 - 15:45 + Panel 25: Industry Trends by Citeline |
|
| + AC Bioscience | + Ariceum Therapeutics | + IKA | ||||
| + Atlyphe (fka Phire) | + Oculis | + CAI Suisse | ||||
| + Leman Biotech | + QBDC | |||||
| + Pilatus | + Ciloa | 16:00 - 16:45 + Panel 18: AI by Sophia Genetics |
16:00 - 16:45 + Panel 22: Exosomes by Cureline AG |
16:00 - 16:45 + Panel 26: Dynamics investors and biotech innovators by AliraHealth |
||
| + Cimeio | + BIO4 Campus | |||||
| + Avrion Therapeutics | ||||||
| 16:00 - 17:00 | Market place of the Global Village Room San Francisco |
|||||
| 17:00 - 18:30 | Evening reception Foyer 2nd floor |
|||||
Floor Map
This interactive floor map helps you to find the booth you are looking for. Find out where each exhibitor is located and receive more information about them by clicking on the booth number on the map.
You can switch between hall 4.1, foyer 2nd floor and foyer 3rd floor by clicking on the icon on top right hand corner.
Panel 1: Driving Clinical Development During Challenging Financial Times
Sponsored by: Fortrea Switzerland AG
Panel 2: How regulators can best support innovation
Regulatory agencies play a pivotal role in supporting Biotech R&D SMEs in their preparation of clinical trials and effective delivery of innovative and reliable therapies to patients. Engaging early with Biotech R&Ds at an early stage increases the chances of complying with regulatory requirements. Experiences and tools of regulators are discussed.
Sponsored by: Swissmedic
Panel 3: Oncology/Neurology
Sponsored by: Innomedica
Panel 4: International Alliances
Panel 5: ADCs & beyond
Panel 6: Innovate & educate
Panel 7: More with less
Sponsored by: Sartorius Stedim Switzerland AG
Panel 8: Drug Discovery for Rare Diseases: from Genes to Treatments
Sponsored by: The Jackson Laboratory (JAX)
Panel 9: Are Current Incentives to Promote Drug Innovation in Healthcare Sustainable?
Sponsored by: Incyte Biosciences Internations Sárl
Panel 10: Maintaining funding flexibility
Panel 11: Womens health (TBD)
Panel 12:
Seeking payer-relevant input into your development plan: focus the development effort to maximize commercial potential
Sponsored by: Syneos Health Switzerland GmbH
Panel 13: For Pitch industrial biotech
Panel 14: Radioligand Therapy
For over a decade, Swiss companies and scientists have been at the forefront of nuclear medicine. As the field of radiotherapeutics continues to grow, how will Switzerland continue to contribute and lead in this next era of innovation for cancer patients? Join us live as we discuss!
Panel 15: Pharma partnering
Panel 16: AI
Sponsored by: Sophia Genetics
Panel 17: Lab automation, diagnostics and analytics
Panel 18: Talent Trek: Biotech’s needs, challenges and opportunities
Panel 19: AMR
Panel 20: Exosomes
Sponsored by: Cureline AG
Panel 21: How data, tech and AI can reimagine health systems
In this panel and short talk, we will explore how leveraging on AI, data and technology we can seize the opportunity for true health systems, re-wiring them to be proactive, predictive and preventive. Join us for an engaging discussion with visionary leaders, brining forward diverse insights into the fast-tracked advancements of digital and health technologies.
Panel 22: Young biotech network
Panel 23: Industry trends
Sponsored by: Citeline
Panel 24: Dynamics investors and biotech innovators
Panel 25: Microbiome
Sponsored by: Pharmabiome
Pitching Session:
BioPitch: Igniting Innovation at Swiss Biotech Day with Nucleate
Discover groundbreaking innovations from Switzerland’s early-stage life science startups at Nucleate’s pitching session. These startups, part of Nucleate’s Activator program, are revolutionizing human health challenges. Run by academic trainees, Nucleate fosters technology commercialization, offering equity-free support and connecting budding entrepreneurs with a prestigious advisor network.
Pitching Session:
Next generation organs on the chip and organoids
Pitching Session:
Recent Developments and Future Avenues in Cell & Gene Therapies
Pitching Session: Digital and health-tech
Come witness the launch of the Swiss Biotech Association chapter Digital and Health-tech! Through this pitching competition you will peek into some of the groundbreaking technologies paving the path of the next healthcare revolution.
Pitching Session: Lab automation, diagnostics and analytics
Join us for a vibrant second edition of the pitching competition linked to the Swiss Biotech Association Chapter – Lab automation, diagnostics and analytics! We selected a cohort of start-ups with disruptive technologies stemming from innovation in laboratory science & automation, novel analytics and screening pipelines & platforms, as well as integrated diagnostics & patient stratification solutions.
Pitching Session: Cooperating and partnering to address critical environmental challenges through Industrial Biotechnology
Industrial Biotechnology (IB) allows for more energy-efficient and sustainable manufacturing processes as well as creating opportunities for abating pollution, using waste and creating new products. It underpins a circular economy, sustainable chemicals industry and can help to protect scarce natural resources. It is likely to impact many aspects of everyday life through new biobased products and processes with far reaching and disruptive impacts. This session starts with the pitches from a number of pioneering early stage Swiss companies. The pitches serve as a basis for an corporate and investor panel sharing their views on how these companies can serve as case studies for the development of the sector.
Host and event manager:
